Menu
Search
|

Menu

Close
X

Audentes Therapeutics Inc BOLD.OQ (NASDAQ Stock Exchange Global Market)

38.90 USD
-- (--)
As of 1:30 AM IST
chart
Previous Close 38.90
Open --
Volume --
3m Avg Volume 141,324
Today’s High --
Today’s Low --
52 Week High 46.12
52 Week Low 15.74
Shares Outstanding (mil) 27.78
Market Capitalization (mil) 722.67
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 12 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
FY15
0
EPS (USD)
FY18
-0.739
FY17
-2.743
FY16
-3.009
FY15
-1.259
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.76
Price to Sales (TTM)
vs sector
--
5.73
Price to Book (MRQ)
vs sector
4.46
5.45
Price to Cash Flow (TTM)
vs sector
--
23.29
Total Debt to Equity (MRQ)
vs sector
2.48
16.72
LT Debt to Equity (MRQ)
vs sector
2.39
12.39
Return on Investment (TTM)
vs sector
-57.99
14.61
Return on Equity (TTM)
vs sector
-145.70
16.34

EXECUTIVE LEADERSHIP

Natalie Holles
President, Chief Operating Officer, Since 2018
Salary: $378,525.00
Bonus: --
Matthew Patterson
Chief Executive Officer, Director, Since 2018
Salary: $479,780.00
Bonus: --
Thomas Schuetz
Co-Founder, Independent Director, Since 2013
Salary: --
Bonus: --
Thomas Soloway
Chief Financial Officer, Senior Vice President, Since 2017
Salary: $378,525.00
Bonus: --
John Gray
Senior Vice President - Research and Development, Chief Scientific Officer, Since 2015
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

600 California St Fl 17
SAN FRANCISCO   CA   94108-2725

Phone: +1415.6386556

Audentes Therapeutics, Inc. is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT). The Company's subsidiary is Audentes Therapeutics UK Ltd. As of September 30, 2016, the Company had not generated any revenues.

SPONSORED STORIES